Clinical Trials

Phase 2 Active not recruiting

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

78 enrolled 15 charts

Hodgkin Disease

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Phase 1 Active not recruiting

Hodgkin Disease

NCT02879695 2025-08-15

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

28 enrolled 16 charts

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

307 enrolled 27 charts

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

3 enrolled 10 charts

Phase 2 Active not recruiting

Hodgkin Disease

NCT03057795 2025-05-07

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

62 enrolled 8 charts

Hodgkin Disease

NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

3 enrolled 8 charts

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT02927769 2025-02-10

CheckMate 744

72 enrolled 24 charts

Hodgkin Disease

NCT03586999 2024-10-29

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

18 enrolled 14 charts

Lymphoma, T-Cell, Peripheral

NCT03061188 2024-06-12

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Phase 1 Completed

15 enrolled 18 charts

Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

131 enrolled 28 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT03310619 2024-04-04

PLATFORM

62 enrolled 41 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03927105 2024-03-18

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

4 enrolled 11 charts

Lymphoma, T-Cell, Peripheral

NCT03495713 2024-01-17

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Phase 2 Terminated

7 enrolled 7 charts

Hodgkin Disease

NCT03138499 2024-01-10

CheckMate 812

Phase 3 Terminated

23 enrolled 14 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Hodgkin Disease

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Phase 1 Completed

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

37 enrolled 6 charts

Hodgkin Disease, Hematologic Neoplasms

NCT02181738 2023-11-28

CheckMate 205

294 enrolled 32 charts

Hodgkin Disease

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

CNSDermatologicLymphoidSarcoma

140 enrolled 23 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

106 enrolled 27 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

93 enrolled 13 charts

Hodgkin Disease

NCT02038946 2022-01-04

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

116 enrolled 14 charts

Lymphoma

NCT02857426 2021-12-23

CheckMate 647

66 enrolled 14 charts

Lymphoma

NCT02038933 2021-10-14

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

121 enrolled 16 charts

Lymphoma, Non-Hodgkin

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

LymphoidOther hematologic neoplasmPlasma cell

47 enrolled 10 charts

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

232 enrolled 17 charts

LymphoidOther solid neoplasm

Advanced Solid Tumors

NCT03075553 2020-04-21

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

12 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Immunoblastic Lymphadenopathy, Mycosis Fungoides, HTLV-I Infections, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02819804 2020-02-11

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 1 Terminated

1 enrolled 7 charts